Allogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and B-Thalassemia
Customize your policy alerts
Sign up for Centene Policy CPMP.108 alerts
Get alerted when Policy CPMP.108 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity criteria and coverage stance for allogeneic hematopoietic cell transplantation (HCT) to treat sickle cell anemia and homozygous B-thalassemia for Centene-affiliated health plans; intended for clinicians and prior authorization staff.
Removed age limit criteria related to high risk of stroke and removed first-degree relative donor requirement for cord blood as the source of stem cells.
Added notes referencing related products (Zynteglo and Casgevy) and Medicare-specific criteria reference.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.